![]() USCAP is known as the largest gathering of M.D. Presenting Author: Andrew Cannon, MD, PhD (Mayo Clinic Pathology) Presentation Location: New Orleans Ernest N. Morial Convention Center in Exhibit Hall B ![]() Andrew Cannon, an anatomic and clinical pathology resident at the Mayo Clinic serves as first author and will be giving the presentation to attendees of USCAP on Tuesday, March 14 th.ĭetails of the presentation are as follows:Ībstract Title: Targeted Mass Spectrometry of Barrett's Esophagus Reveals High-Fidelity Combinatorial Molecular Correlates Along the Metaplasia-Dysplasia-Adenocarcinoma Spectrum Joe Abdo, scientific advisor to ProPhase Labs, serve as co-authors of the study. Dr. Sumeet Mittal, Dr. Catherine Hagen of the Mayo Clinic, Dr. Sheeno Thyparambil of mProbe Inc. and Dr. Hartley, MD of the Mayo Clinic, a board-certified pathologist, and principal investigator of the Collaborative Research Agreement with the Mayo Clinic to assess the performance of the Company's BE-smart Test that detects and quantifies hallmarks of cancer development in tissue of patients diagnosed with Barrett's esophagus, a precancerous condition with high incidence in the United States. The Director of Norton Thoracic Institute, Dr. Readers are cautioned not to place undue reliance on any forward-looking statements contained in this presentation.The senior author of the presentation is Christopher P. The forward-looking statements contained in this presentation are made as of the date hereof, and we do not assume any obligation to update any forward-looking statements except as required by applicable law. ![]() ![]() These forward-looking statements are based on current expectations, estimates, forecasts and projections and are not guarantees of future performance or development. Additional risks and uncertainties relating to our business can be found under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended Decemand our subsequent Quarterly Reports on Form 10-Q, as well as our other filings with the Securities and Exchange Commission. These forward ‐looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from those contemplated, projected, forecasted, estimated or budgeted, whether expressed or implied, by these forward ‐looking statements including risks related to consumer demand for our diagnostic and genomic services, the competitive environment, challenges relating to entering into new business lines, the failure to obtain and maintain certain regulatory approvals, our ability to collect payment for the diagnostic tests we deliver, including our ability to collect payment from uninsured individuals if emergency funding is not allocated to the HRSA uninsured program in the future, and our ability to continue to execute on our business plan. "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions that convey uncertainty or future events or outcomes. ![]() You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," All statements other than statements of historical facts included in this presentation may be deemed to be forward ‐looking statements including statements regarding our strategy, plans, objectives and initiatives, including those related to our plans to expand our in-house clinical testing capabilities and genomics testing offerings and our plans to develop Equivir, Equivir G (Rx) and This presentation contains forward ‐looking statements relating to our strategy and business objectives. ![]()
0 Comments
Leave a Reply. |